Review Article

The Role of PPARγ in the Cyclooxygenase Pathway in Lung Cancer

Saswati Hazra, Katherine A. Peebles, Sherven Sharma, Jenny T. Mao, and Steven M. Dubinett

UCLA Lung Cancer Research Program, Division of Pulmonary and Critical Care Medicine and Hospitalists, Department of Medicine, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA

Correspondence should be addressed to Saswati Hazra, shazra@mednet.ucla.edu

Received 16 April 2008; Revised 18 June 2008; Accepted 8 July 2008

Decreased expression of peroxisome proliferator activated receptor-γ (PPARγ) and high levels of the proinflammatory enzyme cyclooxygenase-2 (COX-2) have been observed in many tumor types. Both reduced (PPARγ) expression and elevated COX-2 within the tumor are associated with poor prognosis in lung cancer patients, and recent work has indicated that these signaling pathways may be interrelated. Synthetic (PPARγ) agonists such as the thiazolidinedione (TZD) class of anti-diabetic drugs can decrease COX-2 levels, inhibit growth of non-small-cell lung cancer (NSCLC) cells in vitro, and block tumor progression in xenograft models. TZDs alter the expression of COX-2 and consequent production of the protumorigenic inflammatory molecule prostaglandin E2 (PGE2) through both (PPARγ) dependent and independent mechanisms. Certain TZDs also reduce expression of PGE2 receptors or upregulate the PGE2 catabolic enzyme 15-prostaglandin dehydrogenase. As several COX-2 enzymatic products have antitumor properties and specific COX-2 inhibition has been associated with increased risk of adverse cardiac events, directly reducing the effects or concentration of PGE2 may provide a more safe and effective strategy for lung cancer treatment. Understanding the mechanisms underlying these effects may be helpful for designing anticancer therapies. This article summarizes recent research on the relationship between (PPARγ), TZDs, and the COX-2/PGE2 pathways in lung cancer.

Copyright © 2008 Saswati Hazra et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Despite the many advances made in diagnostic and treatment strategies, lung cancer remains the leading cause of cancer-related mortality in the United States and is responsible for more deaths than prostate, colon, and breast cancers combined [1]. Investigating the molecular mechanisms underlying the pathogenesis of lung cancer provides opportunities to develop innovative therapies that may reduce suffering due to this devastating disease. Decreased expression of peroxisome proliferator activated receptor (PPARγ) originally identified as a regulator of glucose metabolism and adipocyte differentiation [2] has been associated with poor prognosis in lung cancer patients [3]. PPARγ affects inflammatory gene expression, cell division, apoptosis, invasion, release of proangiogenic cytokines, and differentiation in many cancer types including lung cancer [4–8]. These properties have prompted extensive research on PPARγ in cancer treatment and prevention. Members of the thiazolidinedione (TZD) class of PPARγ agonists are currently approved for treatment of diabetes, and elicit many of the antitumor properties of PPARγ activation through both PPARγ dependent and independent pathways [9–14]. Several studies have demonstrated elevated constitutive expression of the inducible proinflammatory enzyme, cyclooxygenase-2 (COX-2) in human lung cancer [15–19]. Mounting evidence from investigations into the molecular effects of COX-2 over-expression in lung tumor cells indicates that this enzyme has a multifaceted role in conferring the malignant and metastatic phenotypes. The COX-2 enzymatic product prostaglandin E2 (PGE2) has been implicated in apoptosis resistance [20–22], angiogenesis [23, 24], decreased host immunity [25, 26], and enhanced invasion and metastasis [27–29]. This review summarizes investigations in the relationship between PPARγ, its ligands, and COX-2 and PGE2 in lung cancer.

The PPAR family consists of three isoforms: PPARα, PPARγ, and PPARδ, each encoded by different genes. PPARs are members of the nuclear hormone class of receptors and are involved in energy metabolism through transcriptional regulation of specific gene sets. Observations
regarding high PPARγ expression in adipose tissue in combination with its role in lipid and glucose homeostasis led to the development of the TZD class of PPARγ agonists, including troglitazone, cigitazone, rosiglitazone, and pioglitazone as anti-diabetic and insulin-sensitizing drugs. Rosiglitazone and pioglitazone are currently approved for treatment of type 2 diabetes mellitus [30], and this class of drugs has been clinically available for approximately a decade. Some of the TZDs have been shown to exert anti-inflammatory [31], antiproliferative [32], and angiogenic effects [4]. The COX metabolite 15d-PGJ2 is a natural PPARγ ligand and is considered a negative regulator of inflammatory and immune responses [33]. More recent results indicating that PPARγ activation may attenuate inflammatory responses and cancer progression have led to extensive investigation into the role of this protein in inflammation and carcinogenesis.

PPARγ is expressed in human non-small-cell lung cancer (NSCLC) and small cell lung carcinoma [34], and the expression of PPARγ has been correlated with tumor histological type and grade [35]. In NSCLC, decreased PPARγ expression was correlated with poor prognosis [3]. TZDs inhibit tumor formation in a variety of animal models, including colon [36] and lung cancers [37], and PPARγ over-expression protects against tumor development in a mouse model of lung tumorigenesis [38]. Further, increased PPARγ activity promotes epithelial differentiation of NSCLC cells in 3D culture [5]. It has also been shown that PPARγ inhibits the growth of NSCLC in vitro and in vivo [5, 39, 40].

Cyclooxygenase is the rate-limiting enzyme for production of prostaglandins and thromboxanes from free arachidonic acid [41, 42]. Two COX isoforms, COX-1 and COX-2, have been extensively studied. COX-1 is constitutively expressed in most cells and tissues. COX-2 is an inducible enzyme that acts to produce prostaglandins and/or thromboxanes during an acute inflammatory response. The direct enzymatic product of COX-2 and PGH2 is converted to prostaglandins or thromboxanes by individual isomerases or prostaglandin synthases, and relative production of the various COX-2 products depends upon cellular concentrations of down-stream metabolic and catalytic enzymes within the COX-2 pathway. In NSCLC, the major eicosanoid produced is prostaglandin E2 (PGE2) through microsomal PGE2 synthase (mPGES) activity. The nicotinamide adenine dinucleotide positive-dependent catalytic enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH) metabolizes PGE2 to biologically inactive 15-keto derivatives. The final PGE2 concentration experienced by NSCLC cells depends upon expression of PGES and 15-PGDH. A large body of evidence indicates that increased PGE2 production contributes to tumorigenesis. COX-2 over-expression is frequently observed in NSCLC, and the accompanying increased proliferation, invasion, angiogenesis, and resistance to apoptosis have been attributed in part to elevated PGE2 production in the vicinity of the tumor. Thus, COX-2 and its downstream signaling pathways represent potential targets for lung cancer chemoprevention and therapy.

Studies indicate that COX-2 and PPARγ signaling pathways are intertwined. PPARγ ligands suppress COX-2 expression induced by LPS and PMA in macrophages, astrocytes, and epithelial cells [43–45]. The COX-2 metabolite 15d-PGJ2 is an endogenous ligand for PPARγ [46], and during resolution of inflammation elevated 15d-PGJ2 production downregulates COX-2 through a negative feedback loop involving PPARγ and NF-κB [44, 47]. Synthetic and endogenous PPARγ ligands decrease the high COX-2 expression associated with several malignancies including cervical [48] and liver cancers [49] and forced PPAR over-expression decreases COX-2 levels in lung cancer cells [38]. While PPARγ agonists decrease COX-2 expression or prevent COX-2 induction in most settings, COX-2 expression is increased in some studies [50, 51]. For example, Iiwa et al. reported that rosiglitazone (also known as BRL49653) increases COX-2 expression in human colorectal carcinoma cells [52]. PPARγ ligands also have been shown to induce COX-2 expression in mammary epithelial cells [53], monocytes [54], and human synovial fibroblasts [55]. The effect of PPARγ agonists on COX-2 expression may vary based upon the cell type, the specific agonist molecule, and the presence of additional inflammatory mediators. Off-target effects of TZDs may also partially account for differences in the effects of these molecules on COX-2 expression.

Although TZDs are widely known as ligands for PPARγ, they may mediate receptor-independent effects, as previously reported [56–58]. For example, by using embryonic stem cells from PPARγ-null mice, Chawla et al. found that neither macrophage differentiation nor anti-inflammatory effects of synthetic PPARγ ligands are PPARγ receptor-dependent. To distinguish the effects of PPARγ from off-target effects of PPARγ ligands in lung cancer cells, Bren-Mattison et al. utilized a molecular approach to over-express PPARγ in two NSCLC cell lines and assessed the direct effect of PPARγ. Their goal was to determine whether the antitumorigenic effects of PPARγ were mediated via COX-2 pathways in NSCLC. Their results clearly demonstrated that exogenously expressed PPARγ suppresses COX-2 promoter activity and protein expression resulting in suppression of PGE2 production [38]. The COX-2 promoter has binding sites for cAMP response element, NF-IL-6, and NF-κB [59]. Although the COX-2 promoter contains multiple regulatory elements, their data indicate that the inhibitory effects of PPARγ are mediated through NF-κB. Several studies have demonstrated that constitutive activation of NF-κB in tumor cells is mediated through activation of Akt [60, 61]. Bren-Mattison et al. demonstrated that the inhibitory effects of PPARγ on COX-2 were mediated via increased activity of PTEN leading to decreased phospho-Akt and inhibition of NF-κB [38]. These authors further demonstrated that transgenic mice over-expressing PPARγ exhibited reduced COX-2 in type II alveolar epithelial cells of lung, and those mice were protected against lung cancer development in a chemical carcinogenesis mouse model [38]. In summary, these data indicate that COX-2 downregulation may mediate some of the antitumorigenic effects of PPARγ over-expression.

The PPARγ agonists may also affect COX-2 in a PPARγ independent manner (see Table 1). For example, in A549 NSCLC cells troglitazone enhanced both COX-2 and mPGES expression in a concentration dependent manner, resulting
in a marked increase in PGE$_2$ production [62]. Cotreatment with the PPAR$_\gamma$ antagonists GW9662 and bisphenol A diglycidyl ether (BADGE) had no effect on COX-2 induction by troglitazone indicating that this event is PPAR$_\gamma$ independent. Troglitazone increased COX-2 expression at least in part by activating ERK and PI3K pathways, which have been previously demonstrated to influence COX-2 levels [63–65]. Combined troglitazone and TNF$\alpha$ stimulation resulted in additive enhancement of COX-2 expression. The COX-2 metabolite 15d-PGJ$_2$ had no detectable effects on COX-2 or mPGES expression or PGE$_2$ production in A549 cells. This is consistent with the hypothesis that PPAR$_\gamma$-independent mechanisms can partially account for discrepancies in the effects of different TZD drugs on COX-2 expression. Thus, in lung cancer, PPAR$_\gamma$ agonists appear to regulate COX-2 expression and affiliated protumorigenic cellular phenotypes through both PPAR$_\gamma$ dependent and independent means.

We recently examined the effect of the pioglitazone and rosiglitazone on COX-2 and PGE$_2$ levels in A427 and A549 NSCLC cells. Both TZDs inhibited PGE$_2$ production in NSCLC cells via a COX-2 independent pathway. To define the mechanism underlying COX-2 independent suppression of PGE$_2$ production, we focused on the prostaglandin synthases that are responsible for the PGE$_2$ production and on 15PGDH the catabolic enzyme responsible for its degradation to biologically inactive15-keto derivatives [66]. None of the three prostaglandin synthases (microsomal PGES1, PGES2, and cytosolic PGES) was downregulated by pioglitazone or rosiglitazone, however, 15-PGDH was induced by TZDs. TZD-mediated suppression of PGE$_2$ concentration was significantly inhibited by small interfering RNA to 15-PGDH. Studies using dominant-negative PPAR$_\gamma$ over-expression or GW9662 revealed that the induction of 15-PGDH by both pioglitazone and rosiglitazone is PPAR$_\gamma$-independent. These findings indicate that it is possible to use a clinically available pharmacological intervention to suppress tumor-derived PGE$_2$ by enhancing catabolism rather than blocking synthesis. The potential benefits of inhibiting PGE$_2$ levels in a COX-2-independent manner include the following. First, promoting 15-PGDH activity could decrease PGE$_2$ without modifying other prostaglandins such as PGI$_2$. This is potentially important because the latter has been noted to have antitumor properties [67]. It has been suggested that a ratio of PGs may be important in regulating the malignant phenotype. Thus, inhibiting COX-2 activity would diminish both PGE$_2$ and PGI$_2$, whereas selective induction of 15-PGDH could lead to a more favorable PGI$_2$/PGE$_2$ ratio. Second, suppression of PGE$_2$ levels without alteration in COX-2 may limit some of the cardiovascular toxicities associated with COX-2 inhibition [68]. Finally, unlike COX-2 inhibition, which may lead to upregulation of certain leukotrienes that favor malignant progression [69], 15-PGDH induction may lead only to a decrement of PGE$_2$. This speculation will require further investigation.

Different TZDs have the capacity to modulate arachidonic acid metabolism by a variety of pathways (see Figure 1). Recent evidence indicates that ciglitazone induces differentiation and apoptosis in NSCLC [7]. The mechanisms of ciglitazone’s capacity to modulate PGE$_2$ levels in lung adenocarcinoma cells were recently reported [13].

![Figure 1: Effects of various TZDs on the PGE2 pathway.](image-url)

**Table 1: Off-target effects of TZDs in NSCLC.**

| Thiazolidinediones | Molecular effects | Mechanisms | Reference |
|-------------------|------------------|------------|-----------|
| Troglitazone      | ↑ PGE$_2$        | ↑ COX-2, ERK and PI3K phosphorylation | [62] |
| Pioglitazone, Rosiglitazone | ↓ PGE$_2$, ↑ 15-PGDH | ↓ 15-PGDH | [14] |
| Ciglitazone       | ↓ PGE$_2$        | ↓ COX-2    | [13] |
In contrast to pioglitazone and rosiglitazone, ciglitazone mediates COX-2 dependent suppression of PGE2 in NSCLC. Ciglitazone treatment suppressed COX-2 mRNA expression and COX-2 promoter activity but did not modify the expression of enzymes downstream of COX-2 including PGES and 15-PGDH. Utilization of dominant-negative PPAR showed that suppression of COX-2 and PGE2 by ciglitazone is mediated via non-PPAR pathways.

PPARy ligands may also interfere with protumorigenic signals derived from COX-2 by interrupting the function of PGE2 G-protein coupled receptors (GPCRs) designated E-prostanoid (EP) receptors 1–4 [70]. Han and Roman found that in NSCLC cell lines, the PPARy ligands GW1929, 15dPGJ2, ciglitazone, troglitazone, and rosiglitazone significantly decreased EP2 mRNA and protein levels causing growth inhibition in NSCLC cells [71]. The inhibitory effects of rosiglitazone and ciglitazone but not 15d-PGJ2 were suppressed by the PPARy antagonist GW9662 suggesting the involvement of PPARy-dependent and independent mechanisms.

Recently, a retrospective study by Govindarajan et al. demonstrated a significant reduction in lung cancer risk in diabetic patients using the TZD rosiglitazone [72]. Importantly, several clinical studies in diabetes patients have demonstrated an increased risk of cardiovascular events associated with rosiglitazone or pioglitazone treatment [73–75]. This is of particular significance in light of cardiovascular toxicity associated with COX-2 inhibition. Recently, several chemoprevention trials are being initiated using TZDs [74]. However, adverse cardiac events are associated with chronic TZD treatment [74]. Based on these findings, future clinical studies attempting to utilize TZDs in prevention of cancer will require selection of patient populations without cardiovascular risk. Prospective clinical studies specifically designed to address the effects of TZDs on cancer, and cardiac outcomes are required. If the anti-inflammatory and antitumor effects of TZDs are derived through pathways distinct from those leading to cardiovascular toxicity, more selective candidate drug molecules may be therapeutically effective, without leading to adverse cardiac events. Thus, more research is required to define opportunities to specifically interfere with PGE2 production, metabolism, or downstream effects. This could ultimately lead to reduction in lung cancer growth or prevention while leaving the steady-state concentrations of desirable eicosanoids in tact [77].

Both elevated COX-2 and reduced PPARy expression are associated with poor prognosis in lung cancer patients [3, 78–80] and recent work has revealed multiple interactions between PPARy signaling and the COX-2 pathway. The COX-2 product 15d-PGJ2 is an endogenous ligand for PPARy, and PPARy activation as a result of elevated 15d-PGJ2 results in COX-2 downregulation in an autoregulatory feedback loop that may contribute to natural resolution of the inflammatory response [46]. Forced expression of PPARy decreases COX-2 expression in cultured human NSCLC cells and mouse lungs and protects against lung tumor development in a murine model [5, 38]. Synthetic PPARy ligands, several of which are currently approved for treatment of diabetes, can interrupt several stages of the COX-2/PGE2 protumorigenic pathway, although in certain cases PPARy ligands may increase COX-2 expression. These effects are primarily mediated through PPARy-independent pathways (see Table 1). PPARy ligands may directly decrease COX-2 transcription in an NF-kB-dependent manner [38], or they can interfere with downstream targets such as the PGE2 receptor EP2 [71] or the enzyme responsible for PGE2 catabolism, 15-PGDH [66]. The targets downstream of COX-2 may be useful in light of recent evidence that interfering with COX-2 enzymatic activity may increase risk of cardiovascular events [68]. The discovery that certain PPARy agonists can specifically reduce PGE2 concentration or expression of EP receptors may aid in the design of strategies to reduce the effects of harmful prostaglandins without impacting production of critical cardioprotective eicosanoids.

REFERENCES

[1] A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, and M. J. Thun, “Cancer statistics, 2007,” CA: A Cancer Journal for Clinicians, vol. 57, no. 1, pp. 43–66, 2007.
[2] J. Berger and D. E. Moller, “The mechanisms of action of PPARs,” Annual Review of Medicine, vol. 53, pp. 409–435, 2002.
[3] H. Sasaki, M. Tanahashi, H. Yukiue, et al., “Decreased peroxisome proliferator-activated receptor gamma gene expression was correlated with poor prognosis in patients with lung cancer,” Lung Cancer, vol. 36, no. 1, pp. 71–76, 2002.
[4] V. G. Keshamouni, D. A. Arenberg, R. C. Reddy, M. J. Newstead, S. Anthwal, and T. J. Staniford, “PPAR-y activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer,” Neoplasia, vol. 7, no. 3, pp. 294–301, 2005.
[5] Y. Bren-Mattison, V. Van Putten, D. Chan, R. Winn, M. W. Geraci, and R. A. Nemenoff, “Peroxisome proliferator-activated receptor-γ (PPARy) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC),” Oncogene, vol. 24, no. 8, pp. 1412–1422, 2005.
[6] C. G. Su, X. Wen, S. T. Bailey, et al., “A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response,” The Journal of Clinical Investigation, vol. 104, no. 4, pp. 383–389, 1999.
[7] T.-H. Chang and E. Szabo, “Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor γ in non-small cell lung cancer,” Cancer Research, vol. 60, no. 4, pp. 1129–1138, 2000.
[8] S. Han and J. Roman, “Peroxisome proliferator-activated receptor γ: a novel target for cancer therapeutics?” Anti-Cancer Drugs, vol. 18, no. 3, pp. 237–244, 2007.
[9] A. T. Coyle and B. T. Kinsella, “Synthetic peroxisome proliferator-activated receptor γ agonists rosiglitazone and troglitazone suppress transcription by promoter 3 of the human thromboxane A2 receptor gene in human erythrocytes,” Biochemical Pharmacology, vol. 71, no. 9, pp. 1308–1323, 2006.
Endocrinology & Metabolism, vol. 90, no. 7, pp. 3886–3896, 2005.

[11] T. Satoh, M. Toyoda, H. Hoshino, et al., “Activation of peroxisome proliferator-activated receptor-γ stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells,” Oncogene, vol. 21, no. 14, pp. 2171–2180, 2002.

[12] S. J. Baek, L. C. Wilson, L. C. Hsi, and T. E. Eling, “Trogitazona, a peroxisome proliferator-activated receptor γ (PPARγ) ligand, selectively induces the early growth response-1 gene independently of PPARγ. A novel mechanism for its anti-tumorogenic activity,” The Journal of Biological Chemistry, vol. 278, no. 8, pp. 5845–5853, 2003.

[13] S. Hazra and S. M. Dubinett, “Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cells,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 77, no. 1, pp. 51–58, 2007.

[14] S. Hazra, R. K. Batra, H. H. Tai, S. Sharma, X. Cui, and S. M. Dubinett, “Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase,” Molecular Pharmacology, vol. 71, no. 6, pp. 1715–1720, 2007.

[15] M. Huang, M. Stolina, S. Sharma, et al., “Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production,” Cancer Research, vol. 58, no. 6, pp. 1208–1216, 1998.

[16] T. Hida, Y. Yatabe, H. Achiwa, et al., “Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas,” Cancer Research, vol. 58, no. 17, pp. 3761–3764, 1998.

[17] J. Brabender, J. Park, R. Metzger, et al., “Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer,” Annals of Surgery, vol. 235, no. 3, pp. 440–443, 2002.

[18] H. Achiwa, Y. Yatabe, T. Hida, et al., “Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas,” Clinical Cancer Research, vol. 5, no. 5, pp. 1001–1005, 1999.

[19] Y. Hosomi, T. Yokose, Y. Hirose, et al., “Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung,” Lung Cancer, vol. 30, no. 2, pp. 73–81, 2000.

[20] M. Tsuji and R. N. DuBois, “Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2,” Cell, vol. 83, no. 3, pp. 493–501, 1995.

[21] K. Krysan, F. H. Merchant, L. Zhu, et al., “COX-2-dependent stabilization of survivin in non-small cell lung cancer,” The FASEB Journal, vol. 18, no. 1, pp. 206–208, 2004.

[22] K. Krysan, H. Dalwadi, S. Sharma, M. Pöld, and S. Dubinett, “Cyclooxygenase-2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer,” Cancer Research, vol. 64, no. 18, pp. 6359–6362, 2004.

[23] K. M. Leahy, A. T. Koki, and J. L. Masferrer, “Role of cyclooxygenases in angiogenesis,” Current Medicinal Chemistry, vol. 7, no. 11, pp. 1163–1170, 2000.

[24] S. Gately and W. W. Li, “Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy,” Seminars in Oncology, vol. 31, no. 2, supplement 7, pp. 2–11, 2004.

[25] V. C. Liu, L. Y. Wong, T. Jang, et al., “Tumor evasion of the immune system by converting CD4+CD25+ T cells into CD4+CD25– T regulatory cells: role of tumor-derived TGF-β,” The Journal of Immunology, vol. 178, no. 5, pp. 2883–2892, 2007.

[26] F. Baratelli, Y. Lin, L. Zhu, et al., “Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells,” The Journal of Immunology, vol. 175, no. 3, pp. 1483–1490, 2005.

[27] M. Dohadwala, J. Luo, L. Zhu, et al., “Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44+,” The Journal of Biological Chemistry, vol. 276, no. 24, pp. 20809–20812, 2001.

[28] M. Dohadwala, R. K. Batra, J. Luo, et al., “Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion,” The Journal of Biological Chemistry, vol. 277, no. 52, pp. 50828–50833, 2002.

[29] H. Sheng, J. Shao, M. K. Washington, and R. N. DuBois, “Prostaglandin E2 increases growth and motility of colorectal carcinoma cells,” The Journal of Biological Chemistry, vol. 276, no. 21, pp. 18075–18081, 2001.

[30] R. J. Durbin, “Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance,” Diabetes, Obesity & Metabolism, vol. 6, no. 4, pp. 280–285, 2004.

[31] A. Consoli and E. Devangelio, “Thiazolidinediones and inflammation,” Lupus, vol. 14, no. 9, pp. 794–797, 2005.

[32] S. Schmidt, E. Moric, M. Schmidt, M. Sastre, D. L. Feinstein, and M. T. Heneka, “Anti-inflammatory and antiproliferative actions of PPAR-γ agonists on T lymphocytes derived from MS patients,” Journal of Leukocyte Biology, vol. 75, no. 3, pp. 478–485, 2004.

[33] J. U. Scher and M. H. Pillinger, “15d-PGJ2: the anti-inflammatory prostaglandin?” Clinical Immunology, vol. 114, no. 2, pp. 100–109, 2005.

[34] K. Inoue, Y. Kawahito, Y. Tsubouchi, et al., “Expression of peroxisome proliferator-activated receptor (PPAR)-γ in human lung cancer,” Anticancer Research, vol. 21, no. 4A, pp. 2471–2476, 2001.

[35] S. Theocharis, H. Kanelli, E. Politi, et al., “Expression of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade,” Lung Cancer, vol. 36, no. 3, pp. 249–255, 2002.

[36] T. Yoshizumi, T. Ohta, I. Ninomiya, et al., “Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects,” International Journal of Oncology, vol. 25, no. 3, pp. 631–639, 2004.

[37] V. G. Keshamouni, R. C. Reddy, D. A. Arenberg, et al., “Peroxisome proliferator-activated receptor-γ activation inhibits tumor progression in non-small-cell lung cancer,” Oncogene, vol. 23, no. 1, pp. 100–108, 2004.

[38] Y. Bren-Mattison, A. M. Meyer, V. Van Putten, et al., “Antitumorigenic effects of peroxisome proliferator-activated receptor-γ in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-κB,” Molecular Pharmacology, vol. 73, no. 3, pp. 709–717, 2008.

[39] M. Wick, G. Hurteau, C. Dessev, et al., “Peroxisome proliferator-activated receptor-γ is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth,” Molecular Pharmacology, vol. 62, no. 5, pp. 1207–1214, 2002.
[40] S. Han and J. Roman, “Rosiglitazone suppresses human lung carcinoma cell growth through PPARγ-dependent and PPARγ-independent signal pathways,” Molecular Cancer Therapeutics, vol. 5, no. 2, pp. 430–437, 2006.

[41] M. Katori and M. Majima, “Cylooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors,” Inflammation Research, vol. 49, no. 8, pp. 367–392, 2000.

[42] H. R. Herschman, “Prostaglandin synthase 2,” Biochimica et Biophysica Acta, vol. 1299, no. 1, pp. 125–140, 1996.

[43] K. Subbaramaiah, D. T. Lin, C. J. Hart, and A. J. Dannenberg, “Peroxisome proliferator-activated receptor γ ligands suppress the transcriptional activation of cylooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300,” The Journal of Biological Chemistry, vol. 276, no. 15, pp. 12440–12448, 2001.

[44] H. Inoue, T. Tanabe, and K. Umesono, “Feedback control of cylooxygenase-2 expression through PPARγ,” The Journal of Biological Chemistry, vol. 275, no. 36, pp. 28028–28032, 2000.

[45] T. M. McIntyre, G. A. Zimmerman, and S. M. Fischer, “Prostaglandin E2, “The Journal of Biological Chemistry,” vol. 277, no. 6, pp. 5081–5085, 2002.

[46] H. Cho and H.-H. Tai, “Inhibition of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by PPAR activators which are independent of NF-κB,” FEBS Letters, vol. 560, no. 1–3, pp. 30–34, 2004.

[47] B.-C. Chen, Y.-S. Chang, J.-C. Kang, et al., “Peptidoglycan induces nuclear factor-kB activation and cylooxygenase-2 expression via Ras, Raf-1, and ERK in RAW 264.7 macrophages,” The Journal of Biological Chemistry, vol. 279, no. 20, pp. 20889–20897, 2004.

[48] S. A. Weaver, M. P. Russo, K. L. Wright, et al., “Regulatory role of phosphatidylinositol 3-kinase on TNF-α-induced cyclooxygenase 2 expression in colonic epithelial cells,” Gastroenterology, vol. 120, no. 5, pp. 1117–1127, 2001.

[49] H. Cho and H.-H. Tai, “Inhibition of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by cyclooxygenase inhibitors and chemopreventive agents,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 67, no. 6, pp. 461–465, 2002.

[50] R. L. Keith, Y. E. Miller, T. M. Hudish, et al., “Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice,” Cancer Research, vol. 64, no. 16, pp. 5897–5904, 2004.

[51] A. Finckh and M. D. Aronson, “Cardiovascular risk of cyclooxygenase-2 inhibitors: where we stand now,” Annals of Internal Medicine, vol. 142, no. 3, pp. 212–214, 2005.
[69] J. T. Mao, I.-H. Tsu, S. M. Dubinett, et al., “Modulation of pulmonary leukotriene B₄ production by cyclooxygenase-2 inhibitors and lipopolysaccharide,” *Clinical Cancer Research*, vol. 10, no. 20, pp. 6872–6878, 2004.

[70] R. N. DuBois, S. B. Abramson, L. Crofford, et al., “Cyclooxygenase in biology and disease,” *FASEB Journal*, vol. 12, no. 12, pp. 1063–1073, 1998.

[71] S. Han and J. Roman, “Suppression of prostaglandin E₂ receptor subtype EP2 by PPARγ ligands inhibits human lung carcinoma cell growth,” *Biochemical and Biophysical Research Communications*, vol. 314, no. 4, pp. 1093–1099, 2004.

[72] R. Govindarajan, L. Ratnasinghe, D. L. Simmons, et al., “Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes,” *Journal of Clinical Oncology*, vol. 25, no. 12, pp. 1476–1481, 2007.

[73] C. J. Rosen, “The rosiglitazone story—lessons from an FDA advisory committee meeting,” *The New England Journal of Medicine*, vol. 357, no. 9, pp. 844–846, 2007.

[74] “Thiazolidinediones and cardiovascular disease,” *The Medical Letter on Drugs and Therapeutics*, vol. 49, no. 1265, pp. 57–58, 2007.

[75] S. E. Nissen and K. Wolski, “Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes,” *The New England Journal of Medicine*, vol. 356, no. 24, pp. 2457–2471, 2007.

[76] R. A. Nemenoﬀ, M. Weiser-Evans, and R. A. Winn, “Activation and molecular targets of peroxisome proliferator-activated receptor-γ ligands in lung cancer,” *PPAR Research*, vol. 2008, Article ID 156875, 8 pages, 2008.

[77] K. A. Peebles, J. M. Lee, J. T. Mao, et al., “Inflammation and lung carcinogenesis: applying findings in prevention and treatment,” *Expert Review of Anticancer Therapy*, vol. 7, no. 10, pp. 1405–1421, 2007.

[78] H.-S. Kim, H.-R. Youm, J.-S. Lee, K.-W. Min, J.-H. Chung, and C.-S. Park, “Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer,” *Lung Cancer*, vol. 42, no. 2, pp. 163–170, 2003.

[79] F. R. Khuri, H. Wu, J. J. Lee, et al., “Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer,” *Clinical Cancer Research*, vol. 7, no. 4, pp. 861–867, 2001.

[80] H. Tsuochi, N. Sato, M. Hiyama, et al., “Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer,” *The Annals of Thoracic Surgery*, vol. 82, no. 4, pp. 1198–1204, 2006.